Stock LEXX LEXARIA BIOSCIENCE CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Lexaria Bioscience Corp. Stock

Equities

LEXX

US52886N4060

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
2.24 USD -1.10% Intraday chart for Lexaria Bioscience Corp. -3.03% +79.20%
Apr. 16 Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study MT
Apr. 16 Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study CI

Financials (USD)

Sales 2024 * 482K Sales 2025 * 488K Capitalization 28.86M
Net income 2024 * -6M Net income 2025 * -7M EV / Sales 2024 * 59.9 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 59.2 x
P/E ratio 2024 *
-4.19 x
P/E ratio 2025 *
-4.53 x
Employees 5
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.42%
More Fundamentals * Assessed data

Chart Lexaria Bioscience Corp.

Dynamic Chart

Latest news about Lexaria Bioscience Corp.

Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study MT
Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study CI
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents CI
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief MT
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer CI
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Sector Update: Health Care MT
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise MT
Maxim Group Adjusts Lexaria Bioscience Price Target to $12 From $3, Maintains Buy Rating MT
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1 CI
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1 CI
Lexaria Bioscience Corp. Announces 7% Weight Loss in Animals Supports in its Next 8-Week Animal Study CI
Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial CI
Lexaria Bioscience Corp. Submits Investigational New Drug Application CI
More news

Analyst Recommendations on Lexaria Bioscience Corp.

Maxim Group Adjusts Lexaria Bioscience Price Target to $12 From $3, Maintains Buy Rating MT
Maxim Group Initiates Lexaria Bioscience With Buy Rating, $2 Price Target MT
More recommendations

Press releases Lexaria Bioscience Corp.

Lexaria Bioscience : Corporate Highlight Sheet PU
Lexaria Awarded New Patents AQ
Lexaria Bioscience : Amendment of a Material Definitive Agreement - Form 8-K PU
Lexaria to Present at The LD Micro Invitational XIV NE
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer AQ
More press releases

News in other languages on Lexaria Bioscience Corp.

Lexaria Bioscience Corp.: Lexaria beurteilt den Einfluss von DehydraTECH auf die orale Wirksamkeit von GLP-1-Arzneimitteln in Produkten wie Ozempic, Wegovy und Rybelsus sowohl bei alleiniger Gabe als auch in Verbindung mit DehydraTECH-CBD
More news

Quotes and Performance

1 day-1.10%
1 week-3.03%
Current month-38.29%
1 month-35.45%
3 months+47.37%
6 months+68.42%
Current year+79.20%
More quotes

Highs and lows

1 week
2.15
Extreme 2.15
2.41
1 month
1.85
Extreme 1.85
4.00
Current year
1.20
Extreme 1.2
6.85
1 year
0.65
Extreme 0.6488
6.85
3 years
0.65
Extreme 0.6488
12.50
5 years
0.65
Extreme 0.6488
33.00
10 years
0.65
Extreme 0.6488
76.20
More quotes

Managers and Directors - Lexaria Bioscience Corp.

Managers TitleAgeSince
Christopher Bunka CEO
 Chief Executive Officer 62 06-10-25
John Docherty PSD
 President 53 15-04-14
George Jurcic IRC
 Investor Relations Contact - 21-04-30
Members of the board TitleAgeSince
Christopher Bunka CEO
 Chief Executive Officer 62 06-10-25
Nicholas Baxter BRD
 Director/Board Member 70 11-07-07
Albert Reese BRD
 Director/Board Member 74 21-01-13
More insiders

Quotes

Date Price Change Volume
24-04-23 2.24 -1.10% 53,986
24-04-22 2.265 +2.95% 34,458
24-04-19 2.2 -2.22% 61,647
24-04-18 2.25 -3.85% 124,708
24-04-17 2.34 +1.30% 461,093

Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT

More quotes

Company Profile

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.
Sector
Pharmaceuticals
More about the company

Income Statement Evolution

More financial data

Ratings for Lexaria Bioscience Corp.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.24 USD
Average target price
11 USD
Spread / Average Target
+391.07%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
LEXARIA BIOSCIENCE CORP. Stock Lexaria Bioscience Corp.
+79.20% 28.86M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.92% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.06% 570B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.59% 360B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.38% 321B
ABBVIE INC. Stock AbbVie Inc.
+9.39% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+7.36% 217B
NOVARTIS AG Stock Novartis AG
+6.19% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-8.96% 204B
PFIZER, INC. Stock Pfizer, Inc.
-8.58% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LEXX Stock